Skip to main content

Peer Review reports

From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Original Submission
19 Jan 2023 Submitted Original manuscript
23 Feb 2023 Reviewed Reviewer Report
28 Mar 2023 Reviewed Reviewer Report
2 Apr 2023 Author responded Author comments - Thomas Pabst
Resubmission - Version 2
2 Apr 2023 Submitted Manuscript version 2
5 Apr 2023 Author responded Author comments - Thomas Pabst
Resubmission - Version 3
5 Apr 2023 Submitted Manuscript version 3
Publishing
7 Apr 2023 Editorially accepted
15 Apr 2023 Article published 10.1186/s12885-023-10824-3

You can find further information about peer review here.

Back to article page